Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD
Capricor Reported Long-Term Data For Its Cell Therapy
Executive Summary
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
You may also be interested in...
Capricor's DMD Cell Therapy Has HOPE, But Market Is Unsure
Capricor will start a Phase II trial in the first quarter of 2018 for its regenerative cell therapy CAP-1002 in Duchenne muscular dystrophy following positive results in an early-stage trial – the stem cell product was dropped by Capricor's big pharma partner Johnson & Johnson earlier this year.
Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.